Ⅱ® , a calcium hydroxide intracanal medicament, on the percentage of the gutta-percha-filled area(PGP). Methods:Forty-eight simulated straight canals were prepared in clear resin blocks using EndoWave rotary instruments to size 30(0.06 taper)on apical dimensions. Each type of specimens were divided into two groups (n=24), respectively;Calcipex Ⅱ®remaining and without Calcipex Ⅱ® (control)groups. Specimens were filled with gutta-percha and sealer, Thermafil® +Canals® , Thermafil® +Canals® -N,

more »

... rmafil® +Sealapex TM , single-cone+Canals® , single-cone+Canals® -N, and single-cone+Sealapex TM (n=4). All specimens were sectioned horizontally at 1 and 3 mm levels from the working length, and the PGP was measured. Data were analyzed and compared using Kruskal-Wallis and Mann-Whitney tests(P<0.05). Results:At 1 mm, no significant differences were found in PGP of Thermafil® +Canals® -N, single-cone+ Sealapex TM between the Calcipex Ⅱ®remaining groups and without Calcipex Ⅱ®groups(P>0.05). At 3 mm, no significant differences were found in PGP among Thermafil® +Canals® , Thermafil® +Canals® -N, Thermafil® + Sealapex TM , single-cone+Canals® (P>0.05). Conclusions:Thermafil® +Canals® -N was least affected by Calcipex Ⅱ®intracanal medication.